Exscientia

Biotechnology company specializing in the development of artificial intelligence-designed drug candidates for clinical trials. It has pioneered the first clinically-validated AI-driven platform, which aims to enhance treatment outcomes for cancer patients by optimizing drug discovery and development processes. The primary beneficiaries of Exscientia's innovations are cancer patients and healthcare providers seeking advanced, effective treatment options.